vs
Side-by-side financial comparison of Baxter International (BAX) and TANTECH HOLDINGS LTD (TANH). Click either name above to swap in a different company.
Baxter International is the larger business by last-quarter revenue ($3.0B vs $21.5M, roughly 138.4× TANTECH HOLDINGS LTD). TANTECH HOLDINGS LTD runs the higher net margin — 8.2% vs -37.9%, a 46.2% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs -0.2%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
Tantech Holdings Ltd is a China-based specialty manufacturing enterprise focused on R&D, production and distribution of bamboo-derived carbon products, high-performance clean energy materials and eco-friendly consumer goods, serving customers across Chinese and global markets in consumer goods, industrial materials and new energy segments.
BAX vs TANH — Head-to-Head
Income Statement — Q4 2025 vs Q2 2025
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $21.5M |
| Net Profit | $-1.1B | $1.8M |
| Gross Margin | 19.4% | 22.2% |
| Operating Margin | -24.5% | 10.8% |
| Net Margin | -37.9% | 8.2% |
| Revenue YoY | 458.0% | -0.2% |
| Net Profit YoY | -120.3% | 59.8% |
| EPS (diluted) | $-2.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.8B | $21.5M | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $533.0M | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $3.8B | $21.5M | ||
| Q1 24 | $3.6B | — |
| Q4 25 | $-1.1B | — | ||
| Q3 25 | $-46.0M | — | ||
| Q2 25 | $91.0M | $1.8M | ||
| Q1 25 | $126.0M | — | ||
| Q4 24 | $-512.0M | — | ||
| Q3 24 | $140.0M | — | ||
| Q2 24 | $-314.0M | $1.1M | ||
| Q1 24 | $37.0M | — |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 35.3% | 22.2% | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 37.5% | 22.3% | ||
| Q1 24 | 38.6% | — |
| Q4 25 | -24.5% | — | ||
| Q3 25 | 6.1% | — | ||
| Q2 25 | 6.8% | 10.8% | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | 5.7% | — | ||
| Q2 24 | -5.0% | 8.0% | ||
| Q1 24 | 5.2% | — |
| Q4 25 | -37.9% | — | ||
| Q3 25 | -1.6% | — | ||
| Q2 25 | 3.2% | 8.2% | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | -96.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | -8.2% | 5.1% | ||
| Q1 24 | 1.0% | — |
| Q4 25 | $-2.21 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | $0.25 | — | ||
| Q4 24 | $-0.99 | — | ||
| Q3 24 | $0.27 | — | ||
| Q2 24 | $-0.62 | $0.21 | ||
| Q1 24 | $0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $35.2M |
| Total DebtLower is stronger | $9.5B | — |
| Stockholders' EquityBook value | $6.1B | $128.3M |
| Total Assets | $20.1B | $143.0M |
| Debt / EquityLower = less leverage | 1.55× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | $35.2M | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $2.1B | $34.2M | ||
| Q1 24 | $3.0B | — |
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
| Q4 25 | $6.1B | — | ||
| Q3 25 | $7.2B | — | ||
| Q2 25 | $7.3B | $128.3M | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $7.9B | — | ||
| Q2 24 | $7.6B | $126.0M | ||
| Q1 24 | $8.2B | — |
| Q4 25 | $20.1B | — | ||
| Q3 25 | $21.1B | — | ||
| Q2 25 | $21.0B | $143.0M | ||
| Q1 25 | $21.3B | — | ||
| Q4 24 | $25.8B | — | ||
| Q3 24 | $26.7B | — | ||
| Q2 24 | $26.3B | $142.2M | ||
| Q1 24 | $27.8B | — |
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | — | ||
| Q3 25 | $237.0M | — | ||
| Q2 25 | $217.0M | — | ||
| Q1 25 | $-193.0M | — | ||
| Q4 24 | $488.0M | — | ||
| Q3 24 | $253.0M | — | ||
| Q2 24 | $115.0M | $4.4M | ||
| Q1 24 | $163.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $4.4M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 20.6% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.38× | — | ||
| Q1 25 | -1.53× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | — | 4.01× | ||
| Q1 24 | 4.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
TANH
| Revenue from China | $20.9M | 97% |
| Revenue directly from foreign countries | $602.2K | 3% |
